Drug Profile
Research programme: antimalarials - Daiichi Sankyo/Medicines for Malaria Venture
Latest Information Update: 28 Dec 2022
Price :
$50
*
At a glance
- Originator Daiichi Sankyo Company
- Developer Daiichi Sankyo Company; Medicines for Malaria Venture
- Class
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Malaria
Most Recent Events
- 28 Dec 2022 No recent reports of development identified for research development in Malaria in Japan
- 21 Dec 2020 Early research development is still ongoing Japan
- 08 Dec 2020 Daiichi Sankyo and Medicines for Malaria Venture receives grant from Global Health Innovative Technology Fund for antimalarials development in Malaria